Gilead Sciences, Inc. has announced groundbreaking results from its Phase 3 PURPOSE 1 trial, showing that their injectable HIV-1 capsid inhibitor, lenacapavir, achieved 100% efficacy in preventing HIV infections in cisgender women. The study met key efficacy endpoints, leading an independent Data Monitoring Committee to recommend stopping the trial and offering lenacapavir to all participants. These results mark a significant advancement in HIV prevention, with zero infections reported in the lenacapavir group. The trial compared lenacapavir to daily oral Truvada and Descovy, with lenacapavir demonstrating superiority in prevention. This data is part of Gilead’s comprehensive PURPOSE program, aiming to innovate HIV prevention globally. Further trials for lenacapavir in different populations are ongoing, showing promise in expanding HIV prevention options. Gilead remains committed to ending the HIV epidemic and providing access to life-saving treatments globally.